The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2 ; volume:18 ; number:1 ; day:1 ; month:3 ; year:2018 ; pages:1-14 ; date:12.2018
BMC cancer ; 18, Heft 1 (1.3.2018), 1-14, 12.2018
- Urheber
-
Maadi, Hamid
- Beteiligte Personen und Organisationen
-
Nami, Babak
Tong, Junfeng
Li, Gina
Wang, Zhixiang
SpringerLink (Online service)
- DOI
-
10.1186/s12885-018-4143-x
- URN
-
urn:nbn:de:1111-201805039039
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Maadi, Hamid
- Nami, Babak
- Tong, Junfeng
- Li, Gina
- Wang, Zhixiang
- SpringerLink (Online service)
Ähnliche Objekte (12)
Photoimmunotherapy of HER2-expressing Breast Cancer Cells
Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro
Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation
Photoimmunotherapy of HER2-expressing Breast Cancer Cells
Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro
Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation
Photoimmunotherapy of HER2-expressing Breast Cancer Cells
Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro
Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients